Thursday, March 26, 2015 11:00:57 PM
SAN FRANCISCO and GENEVA, July 1, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced it has independently confirmed MANF's activity in mitigating tau hyperphosphorylation in pre-clinical models of Alzheimer's disease. The studies commissioned by Amarantus independently confirm data published in 2012 in the Chinese Pharmacological Bulletin entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" in which the authors demonstrated that MANF had a pronounced effect in reducing Tau hyperphosphorylation, reducing cell death, and improving overall cellular health in in vitro models of Alzheimer's disease.
"There has been a high degree of concern of late that data produced in China may not reproduce in Western labs," said Gerald E. Commissiong, President & CEO of Amarantus. "We are extremely pleased that the Company was able to reproduce these exciting findings, especially in light of our growing interest in the Asian market. What this tells us is that good science is currently being conducted on MANF in China, and we believe we can leverage this to the benefit of shareholders. China is continuing to emerge as a powerhouse across all sectors, including biotechnology. Establishing relationships in that part of the world early on will be tremendously valuable as we seek to fully exploit our MANF technology. Alzheimer's disease is a global problem that we believe will require global solutions."
In in vitro models of Alzheimer's disease, MANF improved cell viability and reduced tau hyperphosphorylation believed to be directly associated with human Alzheimer's disease. The data demonstrated a robust activity consistent with positive controls. The Company will begin to map out a strategy to evaluate MANF activity in animal models of Alzheimer's disease as part of its broader MANF research program.
http://globenewswire.com/news-release/2014/07/01/648005/10087765/en/Amarantus-Independently-Confirms-Published-Chinese-Positive-MANF-Tau-Phosphorylation-Data-for-Alzheimer-s-Disease.html
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM